Weinberger Paul, Ponny Sithara Raju, Xu Hongyan, Bai Shan, Smallridge Robert, Copland John, Sharma Ashok
1 Center for Biotechnology and Genomic Medicine, Medical College of Georgia at Augusta University , Augusta, Georgia .
2 Department of Otolaryngology, Medical College of Georgia at Augusta University , Augusta, Georgia .
Thyroid. 2017 Feb;27(2):236-252. doi: 10.1089/thy.2016.0285. Epub 2016 Dec 15.
Anaplastic thyroid carcinoma (ATC) accounts for only 3% of thyroid cancers, yet strikingly, it accounts for almost 40% of thyroid cancer deaths. Currently, no effective therapies exist. In an effort to identify ATC-specific therapeutic targets, we analyzed global gene expression data from multiple studies to identify ATC-specific dysregulated genes.
The National Center for Biotechnology Information Gene Expression Omnibus database was searched for high-throughput gene expression microarray studies from human ATC tissue along with normal thyroid and/or papillary thyroid cancer (PTC) tissue. Gene expression levels in ATC were compared with normal thyroid or PTC using seven separate comparisons, and an ATC-specific gene set common in all seven comparisons was identified. We investigated these genes for their biological functions and pathways.
There were three studies meeting inclusion criteria, (including 32 ATC patients, 69 PTC, and 75 normal). There were 259 upregulated genes and 286 downregulated genes in ATC with at least two-fold change in all seven comparisons. Using a five-fold filter, 36 genes were upregulated in ATC, while 40 genes were downregulated. Of the 10 top globally upregulated genes in ATC, 4/10 (MMP1, ANLN, CEP55, and TFPI2) are known to play a role in ATC progression; however, 6/10 genes (TMEM158, CXCL5, E2F7, DLGAP5, MME, and ASPM) had not been specifically implicated in ATC. Similarly, 3/10 (SFTA3, LMO3, and C2orf40) of the most globally downregulated genes were novel in this context, while 7/10 genes (SLC26A7, TG, TSHR, DUOX2, CDH1, PDE8B, and FOXE1) have been previously identified in ATC. We experimentally validated a significant correlation for seven transcription factors (KLF16, SP3, ETV6, FOXC1, SP1, EGFR1, and MAFK) with the ATC-specific genes using microarray analysis of ATC cell lines. Ontology clustering of globally altered genes revealed that "mitotic cell cycle" is highly enriched in the globally upregulated gene set (44% of top upregulated genes, p-value <10).
By focusing on globally altered genes, we have identified a set of consistently altered biological processes and pathways in ATC. Our data are consistent with an important role for M-phase cell cycle genes in ATC, and may provide direction for future studies to identify novel therapeutic targets for this disease.
间变性甲状腺癌(ATC)仅占甲状腺癌的3%,但令人惊讶的是,它却占甲状腺癌死亡病例的近40%。目前尚无有效的治疗方法。为了确定ATC特异性的治疗靶点,我们分析了多项研究的全基因组表达数据,以识别ATC特异性失调基因。
在国家生物技术信息中心基因表达综合数据库中搜索来自人类ATC组织以及正常甲状腺和/或乳头状甲状腺癌(PTC)组织的高通量基因表达微阵列研究。使用七项独立比较将ATC中的基因表达水平与正常甲状腺或PTC进行比较,并确定在所有七项比较中均常见的ATC特异性基因集。我们研究了这些基因的生物学功能和信号通路。
有三项研究符合纳入标准(包括32例ATC患者、69例PTC患者和75例正常对照)。在所有七项比较中,ATC中有259个上调基因和286个下调基因,变化倍数至少为两倍。使用五倍筛选标准,ATC中有36个基因上调,40个基因下调。在ATC中全球上调最明显的10个基因中,4/10(基质金属蛋白酶1、锚蛋白、中心体蛋白55和组织因子途径抑制物2)已知在ATC进展中起作用;然而,6/10的基因(跨膜蛋白158、趋化因子配体5、E2F转录因子7、Dlg装配因子5、膜金属蛋白酶和异常纺锤体样微管相关蛋白)尚未被明确认为与ATC有关。同样,在这种情况下,全球下调最明显的10个基因中有3/10(鳞状细胞癌抗原3、LIM结构域蛋白3和2号染色体开放阅读框40)是新发现的,而7/10的基因(溶质载体家族26成员7、甲状腺球蛋白、促甲状腺激素受体、双氧化酶2、钙黏蛋白1、磷酸二酯酶8B和叉头框E1)此前已在ATC中被发现。我们通过对ATC细胞系进行微阵列分析,实验验证了7种转录因子(Krüppel样因子16、SP转录因子3、ETS变异体6、叉头框C1、SP转录因子1、表皮生长因子受体1和MAF bZIP转录因子K)与ATC特异性基因之间存在显著相关性。对全球变化基因的本体聚类分析显示,“有丝分裂细胞周期”在全球上调基因集中高度富集(上调最明显的基因中有44%,p值<10)。
通过关注全球变化的基因,我们在ATC中确定了一组持续变化的生物学过程和信号通路。我们的数据表明M期细胞周期基因在ATC中具有重要作用,可能为未来研究确定该疾病的新治疗靶点提供方向。